𝔖 Bobbio Scriptorium

✦ LIBER ✦

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

✍ Scribed by H. R. BÜLLER; J. L. HALPERIN; H. BOUNAMEAUX; M. PRINS

Book ID: 109152430
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 88 KB
Volume: 6
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2008.02848.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV92 ARE DOUBLE-BLIND, DOUBLE-DUMMY STU

PCV92 ARE DOUBLE-BLIND, DOUBLE-DUMMY STUDIES SUITABLE FOR RESOURCE UTILISATION ANALYSES? AN EXAMPLE FROM A NEW ORAL ANTICOAGULANT FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) FOLLOWING ORTHOPAEDIC SURGERY

✍ N Roskell; S Wolowacz; AV Christiansen; JM Plumb 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

A novel therapeutic approach for multipl

A novel therapeutic approach for multiple sclerosis: Preliminary results of the Israeli linomide, double-blind placebo controlled study in secondary progressive M.S. with monthly MRI evaluation

✍ D. Karussis; Z. Meiner; D. Lehmann; H. Ovadia; R. Mizrachi-Koll; O. Abramsky 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 153 KB

A prospective, multi-center, randomized,

A prospective, multi-center, randomized, double-blind feasibility study to evaluate the safety and performance of hydros joint therapy and Hydros-TA joint therapy for management of pain associated with osteoarthritis in the knee

✍ R.J. Petrella; P. Eamans; J. Alleyne; M. Maroney 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 187 KB

A Novel 12-Week Study, with Three Random

A Novel 12-Week Study, with Three Randomized, Double-Blind Placebo-Controlled Periods to Evaluate Fentanyl Buccal Tablets for the Relief of Breakthrough Pain in Opioid-Tolerant Patients with Noncancer-Related Chronic Pain

✍ John T. Farrar; John Messina; Fang Xie; Russell K. Portenoy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 737 KB

P.1.030 Double-blind, placebo-controlled

P.1.030 Double-blind, placebo-controlled,multicenter study evaluating nemifitide, a new pentapeptide antidepressant, when given daily or every other day for three weeks in the treatment of major depressive disorder

✍ J.P. Feighner; L. Sverdlov; J. Hlavka; G. Nicolau; G. Tonelli; J. Freed 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Prospective evaluation of early virologi

Prospective evaluation of early virological response associated with 40 kDa peginterferon alfa-2A (PEGASYS®) plus ribavirin therapy from a phase III, ranodmized, double-blind study examining the effects of treatment duration and ribavirin dosing: Stephanos J Hadziyannis, Hippokration General Hospital, Athens Greece; Hugo Cheinquer, Univ Fed do Rio Grande do Sul, Porto Alegre RS Brazil; Timothy Morgan, VA Medical Center, Long Beach, CA; Moises Diago, Hospital General de Valencia, Valencia Spain; Donald M Jensen, Rush-Presbyterian-St Luke's Hospital, Chicago, IL; Hoel Sette, Instituto de Infectologia Emilio Ribas, Sao Paulo Brazil; Giuliano Ramadori, Universitatsklinik Gottingen, Gottingen Germany; Henry C Bodenheimer Jr., Mount Sinai Hospital School of Medicine, New York, NY; Jean-Pierre Zarski, CHU de Grenoble, Hopital de la Tronche, Grenoble France; Shou-Dong Lee, Taipei Veterans General Hospital, Taipei Taiwan; Philipa Roberts, Andrew M Ackrill, Roche Products Ltd, Welwyn Garden City Uk

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB